HORAMA appoints life sciences veteran Benedikt Timmerman as new Chairman
HORAMA appoints life sciences veteran Benedikt Timmerman as new Chairman Paris, France, May 18, 2020 ‐ HORAMA, a clinical stage gene therapy company in ophthalmology, today announced that seasoned life sciences executive Dr. Benedikt Timmerman is taking over as the firm’s new Chairman. Benedikt has over 25 years of experience building and leading businesses in […]
Read Post
Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients
Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients NEW YORK, May 13, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and […]
Read Post
Novadip Biosciences Reports Positive Interim Analysis of Phase I/II Bone Non-Union Study with NVD003
Novadip Biosciences Reports Positive Interim Analysis of Phase I/II Bone Non-Union Study with NVD003 – Bone healing demonstrated at six-months after treatment with favorable safety profile – NVD003 is an autologous cell-based osteogenic product Mont-Saint Guibert, Belgium, 13 May, 2020: Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company leveraging its proprietary tissue regeneration […]
Read Post
HORAMA appoints industry veteran Ian Catchpole as Chief Scientific Officer
HORAMA appoints industry veteran Ian Catchpole as Chief Scientific Officer Paris, France, May 4, 2020 ‐ HORAMA, a clinical stage gene therapy company in ophthalmology, today announced the appointment of Dr. Ian Catchpole as its Chief Scientific Officer. Ian will draw on his 25‐ plus years of experience in drug discovery and development to oversee […]
Read Post
Immunic, Inc. Announces Pricing of $15 Million Financing
Immunic, Inc. Announces Pricing of $15 Million Financing NEW YORK, April 23, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has entered into securities purchase agreements with certain institutional investors, led by Altium […]
Read Post
Aelin Therapeutics appoints Alexander Scheer, Ph.D., as Chief Scientific Officer
Aelin Therapeutics appoints Alexander Scheer, Ph.D., as Chief Scientific Officer Dr. Scheer brings over 25 years of international life science experience in multiple disciplines, technologies and therapeutic areas Leuven, BELGIUM – 23 April 2020 – Aelin Therapeutics NV, an emerging biotechnology company focused on the discovery and development of breakthrough Pept-in™-based therapeutics with novel […]
Read Post
Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients
Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients – In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 – – Live Webcast will be Held at 8:00am […]
Read Post
iTeos Therapeutics Closes $125 Million Series B2 Financing
iTeos Therapeutics Closes $125 Million Series B2 Financing – Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint – – Oversubscribed round co-led by new investors RA Capital Management and Boxer Capital – – New investors Janus Henderson Investors, RTW Investments and Invus also participated along with […]
Read Post
eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations
eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations Niel, Belgium: eTheRNA Immunotherapies nv (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium has been formed with North American and European partners […]
Read Post
HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies
HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies Further expansion of HORAMA gene therapy portfolio to treat Inherited Retinal Dystrophies to lead to second clinical program by 2023 Paris (France) and Leiden (Netherlands), March 18, 2020 ‐ HORAMA SA, a French biotechnology company focusing […]
Read Post
Job opening at Fund+ / Internship
Job opening Internship Fund+ is seeking an Intern to support its team during a 3-6 month placement. We are looking for someone with passion for life sciences and startups and make the first step to develop a career in Venture Capital investments. Our purpose is to make long term investments in highly innovative, life science companies primarily active in […]
Read Post
Job opening at Fund+ / Senior Associate
Job opening Senior Associate Fund+ is seeking a Senior Associate who can contribute to the value creation of our investments. Our purpose is to make long term investments in highly innovative, life science companies primarily active in therapeutics, as well as companies developing diagnostics and medical devices, with strong long-term potential. The combination of our open-ended […]
Read Post
HORAMA strengthens its management team with the appointment of Rodolphe Clerval as Chief Business Officer (CBO)
HORAMA strengthens its management team with the appointment of Rodolphe Clerval as Chief Business Officer (CBO) Paris, France, March 11th, 2020 – HORAMA, a clinical stage gene therapy company in ophthalmology, today announced that Rodolphe Clerval has been appointed as Chief Business Officer (CBO). Rodolphe has a strong track record of executing strategic partnerships, business […]
Read Post
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers – First patient enrolled in dose escalation portion of Phase 1/2 study of EOS-448, an antagonist anti-TIGIT antibody that enables antibody dependent cellular cytotoxicity (ADCC) – – ADCC-enabled TIGIT programs are progressing into pivotal trials –– – clinical data expected in […]
Read Post
La Wallonie octroie 15 millions à iTeos
La Wallonie octroie 15 millions – iTeos
Read Post
Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD
Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD Leriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selective PPARγ agonist, is currently in late-stage development for treatment of severe orphan CNS disorders, including X-ALD and Friedreich’s Ataxia. It previously received Orphan Drug Designation from EMA and FDA for both […]
Read Post
Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science
Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science Mont-Saint Guibert, Belgium, 4 December, 2019: Novadip Biosciences (“Novadip” or “the company”), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it is presenting data in a series […]
Read Post
Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia
Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPARγ agonist Second Orphan Drug Designation granted by the European Commission for leriglitazone, in addition to X-linked adrenoleukodystrophy (X-ALD) Orphan Drug Status provides a number of […]
Read Post
Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS
Notice of Business Alliance between Promethera® Biosciences SA and MEDIPAL HOLDINGS – Bringing Innovative Liver-Focused Cell Therapies to Japanese Markets – Promethera® Biosciences SA (“Promethera®“) and MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) today announced that they have entered into a business alliance agreement. In conjunction with today’s alliance, MEDIPAL has decided to increase its shareholdings in the […]
Read Post
EyeD Pharma CEO Melanie Mestdagt in the news
EyeD Pharma CEO Melanie Mestdagt in the news
Read Post
Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia
Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPARγ agonist Second Orphan Drug Designation granted by the FDA for leriglitazone in addition to X-linked adrenoleukodystrophy (X-ALD) Potential for seven years of marketing exclusivity in the USA upon approval in […]
Read Post
Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson
Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson SAN DIEGO, Oct. 15, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamar Howson, a highly seasoned life sciences executive, […]
Read Post
Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis – Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 – SAN DIEGO, Oct. 10, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, […]
Read Post
Minoryx: Un axe Espagne-Belgique pour sauter la barrière
Minoryx News Article: Un axe Espagne-Belgique pour sauter la barrière
Read Post